[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemiplegia-andor-hemiparesis-following-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemiplegia-andor-hemiparesis-following-stroke":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,71,98,141,169,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100631966","immediate-effects-of-pettlep-based-aomi-on-upper-limb-kinematics-in-stroke-survivors-100631966",false,"NCT07507552","Immediate Effects of PETTLEP-Based AOMI on Upper Limb Kinematics in Stroke Survivors","Immediate Effects of PETTLEP-Based AOMI on Upper Limb Kinematics in Stroke Survivors: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Female and male adults aged 40 to 80 years with a diagnosis of unilateral ischemic or hemorrhagic stroke.\n* Residual voluntary movement activity of the affected upper limb.\n* Mild to moderate spasticity (Modified Ashworth Scale ≤ 3).\n* Adequate cognitive function to understand and follow verbal instructions (Mini-Mental State Examination ≥ 21).\n* Medically stable patients, with no active or uncontrolled systemic illness.\n* Ability to sit unsupported for at least 30 minutes and be able to perform brief cognitive-motor exercises.\n\nExclusion Criteria:\n\n* Other central nervous system disorders (e.g., Parkinson's disease, multiple sclerosis, traumatic brain injury).\n* Musculoskeletal or orthopedic conditions causing restriction of movement in the upper-limb (such as fixed contractures, severe joint deformities, shoulder subluxation).\n* Severe sensory deprivation, visual neglect, or inattention that interferes with completion of the task or the ability to engage in motor imagery.\n* Uncontrolled seizures, severe cardiovascular instability, or any other contraindication to imagery.","ALL","40 Years","80 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to investigate the immediate effects of a mental practice technique, called Physical, Environment, Task, Timing, Learning, Emotion, Perspective (PETTLEP)-based Action Observation and Motor Imagery (AOMI), on arm movement in stroke survivors. Stroke often causes difficulty in moving the arm smoothly, leading patients to compensate by using their back or shoulder. In this study, participants will either receive a single session of the AOMI training (watching and mentally practicing a reach-to-grasp movement) or a control relaxation task. The researchers will use a smartphone-based motion capture system (OpenCap) to measure if the mental practice immediately improves the smoothness of the arm movement and reduces compensatory body movements.",[27,28,29],"Stroke","Hemiplegia","Hemiplegia and\u002For Hemiparesis Following Stroke",[31,32,27,33,34,35],"Motor imagery","Action observation","OpenCap","Kinematics","Upper limb rehabilitation","NOT_YET_RECRUITING","2026-04-05",{"date":39,"type":40},"2026-04-09","ACTUAL",{"date":42,"type":21},"2026-04-01",{"date":44,"type":21},"2027-03-20",{"name":46,"class":47},"Istinye University","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100631494","high-intensity-laser-therapy-in-hemiplegic-shoulder-pain-100631494","NCT07501416","High-Intensity Laser Therapy in Hemiplegic Shoulder Pain","Effectiveness of High-Intensity Laser Therapy Combined With Exercise on Clinical and Ultrasonographic Outcomes in Patients With Hemiplegic Shoulder Pain","Inclusion Criteria:\n\n* Age 30-75 years\n* Hemiplegic shoulder pain after stroke\n* Stroke within last 6 months\n* VAS ≥ 3 for pain\n* Medically stable\n\nExclusion Criteria:\n\n* Neurological disorders (MS, Parkinson, etc.)\n* Recent shoulder surgery\u002Finjection\n* Botulinum toxin (last 6 months)\n* Malignancy\n* Pregnancy\n* Epilepsy or photosensitivity\n* Cognitive impairment","30 Years","75 Years",{"count":58,"type":21},60,[24],"This randomized, sham-controlled clinical trial aims to evaluate the effectiveness of high-intensity laser therapy (HILT) combined with exercise on pain, functional status, disability, and ultrasonographic findings in patients with hemiplegic shoulder pain following stroke.",[29],"2026-03-26",{"date":64,"type":40},"2026-03-30",{"date":42,"type":21},{"date":67,"type":21},"2027-01-30",{"name":69,"class":47},"Kutahya Health Sciences University",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":16,"minAge":80,"maxAge":18,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":70},"100557661","effect-of-transcutaneous-electrical-nerve-stimulation-on-post-stroke-patients-100557661","NCT06541015","Effect of Transcutaneous Electrical Nerve Stimulation on Post-stroke Patients","TENS (Transcutaneous Electrical Nerve Stimulation): Effect of Transcutaneous Spinal Direct Current Stimulation on Lower Limb Reflex, Volitional, and Functional Movement Post-stroke","TENS","Post Stroke Cohort:\n\nInclusion Criteria:\n\n* History of single unilateral stroke with subsequent lower limb hemiparesis on either side (\\> 6 months since onset)\n* Ability to walk as part of activities of daily living\n* Age between 18 and 80\n\nExclusion Criteria:\n\n* Presence of concurrent severe medical illness including unhealed pressure sore, active or untreated infection, thromboembolic disease, severe contracture, osteoporosis, heterotropic classification, lower limb fracture, severe pulmonary disease or cardiovascular instability, uncontrolled seizure, uncontrolled diabetes\n* History of any neurological injury other than a single stroke\n* Has received a Botox injection in the lower extremity within the last 4 months\n* Any cognitive deficit that would prevent informed consent or ability to perform the experiment\n* History of prior injury or surgery to the hip or knee\n* Presence of significant lower extremity edema - Presence of cardiac pacemaker or any other electrically implanted device - Use of braces limiting harness\u002FLokomat fit (Any spinal orthoses such as TLSO, HALO)\n* Weight greater than 300 pounds\n* Adults unable to consent, infants, children, teenagers, pregnant women and prisoners will not be included in the study\n* Clinically significant depression, psychiatric disorders, or ongoing drug abuse\n* Actively taking medications with agents known to increase (e.g. amphetamines) or decrease motor system excitability\n* Suffered a concussion in the last 6 months.\n* Unexplained headaches\n\nHealthy Cohort:\n\nInclusion Criteria:\n\n* No history of stroke, cerebral palsy, injury or surgery to the lower limb.\n* Currently not taking any central nervous system (CNS) affecting medication.\n* Ability to walk as part of activities of daily living\n* Age between 18 and 80\n\nExclusion Criteria:\n\n* Presence of concurrent severe medical illness including unhealed pressure sore, active or untreated infection, thromboembolic disease, severe contracture, osteoporosis, heterotropic classification, lower limb fracture, severe pulmonary disease or cardiovascular instability, uncontrolled seizure, uncontrolled diabetes\n* History of any neurological injury\n* Taking any medication affecting change in CNS\n* Any cognitive deficit that would prevent informed consent or ability to perform the experiment\n* History of prior injury or surgery to the hip or knee\n* Presence of significant lower extremity edema - Presence of cardiac pacemaker or any other electrically implanted device - Use of braces limiting harness\u002FLokomat fit (Any spinal orthoses such as TLSO, HALO)\n* Weight greater than 300 pounds\n* Adults unable to consent, infants, children, teenagers, pregnant women and prisoners will not be included in the study\n* Clinically significant depression, psychiatric disorders, or ongoing drug abuse\n* Actively taking medications with agents known to increase (e.g. amphetamines) or decrease motor system excitability\n* Suffered a concussion in the last 6 months.\n* Unexplained headaches\n* Has received a Botox injection in the lower extremity within the last 4 months",true,"18 Years",{"count":82,"type":21},100,[24],"The subjects will be asked to attend minimum 15 separate sessions, 6 for testing changes in reflex behaviors, 3 for testing changes in the influence of descending motor tracts on spinal motor neurons, 3 for each testing functional movement in response to a trip event and cross-tilt walking adaptation pattern, as part of their participation in the research study. The estimated amount of time to enroll and collect the data for each of the subjects is four months' time. The data will be analyzed and ready for grant preparation (if successful) in approximately four months after the start of the study.",[29,86],"Anterior Circulation Stroke of Uncertain Pathology",[88],"Single unilateral stroke with single lower limb hemiparesis","RECRUITING","2026-03-25",{"date":64,"type":40},{"date":93,"type":40},"2019-06-21",{"date":95,"type":21},"2026-12-31",{"name":97,"class":47},"University of Texas Southwestern Medical Center",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":109,"conditions":110,"keywords":121,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":70},"100597086","phase-1-psychedelic-healing-adjunct-therapy-harnessing-opened-malleability-100597086","NCT07053917","Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","PHATHOM","Inclusion Criteria:\n\n* Over age 18 years, inclusive.\n* Ischemic or hemorrhagic stroke confirmed by CT or MRI, at least 12 months prior to admission date\n* Ability to give informed consent and understand the tasks involved.\n* Agree that, for the study duration, will refrain from: (1) No new prescription medications during the time of the study without approval of the study team, (2) taking any herbal supplement (except with prior approval of the research team), (3) taking any nonprescription medications with the exception of: 1. non-steroidal anti-inflammatory drugs. 2. acetaminophen. 3. vitamins. 4. or other over-the-counter medications approved by the research team\n* Are willing to follow restrictions and guidelines concerning medications, consumption of food, beverages, and nicotine the night before and just prior to psilocybin administration.\n* Agree to have transportation other than driving themselves home or to where the participants are staying after the administration of psilocybin.\n* Are willing to be contacted via telephone for all necessary telephone contacts.\n* Must have a negative pregnancy test if able to bear children.\n* Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal.\n* Must agree to inform the investigators within 48 hours of any new medical conditions and procedures.\n* Are proficient in speaking and reading English.\n* Agree to have all clinical visit sessions recorded to audio and video.\n* Agree to not participate in any other interventional clinical trials during the duration of this study.\n\nExclusion Criteria:\n\n* Taking one of the following medications in the 30 days prior to psilocybin administration:\n\n  1. selective serotonin reuptake inhibitor (SSRI)\n  2. Serotonin-norepinephrine reuptake inhibitors (SNRI)\n  3. Buproprion\n  4. Valproic acid\n  5. Zolpidem\n  6. Trazodone\n  7. Carbamazepine.\n  8. tricyclic antidepressants\n  9. Monoamine Oxidase Inhibitors\n  10. Mirtazapine\n\n  l. Lithium m. Buspirone n. Atypical antipsychotics o. Zolpidem p.Carbamazepine q. Clonazepam r. Gabapentin s. Lamotrigine t. Levetiracetam u. Phenobarbital v. Phenytoin w. Topiramate x. Valproic Acid y. Zonisamide\n* History of medically significant suicide attempt.\n* Evidence of acute cardiac dysfunction as evidenced by either elevated troponin or EKG changes within 48 hours of administration.\n* Systolic blood pressure that is greater than 150 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Diastolic blood pressure that is greater than 100 mmHg systolic on \\> 2 readings during the 7-day monitoring period AND blood pressure medication management has been assured.\n* Systolic blood pressure is less than 90 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Diastolic blood pressure is less than 30 mmHg systolic on \\> 2 readings during the 7-day monitoring period after blood pressure medication management has been assured.\n* Systolic blood pressure exceeds 160 mmHg or is less than 90 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Diastolic blood pressure exceeds 100 mmHg or is less than 30 mmHg immediately prior to administration of psilocybin; patients are allowed to be on anti-hypertensives.\n* Cognitive impairment that, in the estimation of the study team, would preclude the use of the MindPod Dolphin.\n* History of physical or neurological condition that interferes with study procedures or assessment of motor function (e.g. severe arthritis, severe neuropathy, Parkinson's disease).\n* Social and\u002For personal circumstances that interfere with ability to perform follow up assessments.\n* Are pregnant or nursing.\n* Weigh less than 48 kg.\n* Are not able to give adequate informed consent.\n* Are actively abusing opioids, cocaine, Phencyclidine (PCP), amphetamines, or alcohol.\n* Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-5) criteria for moderate or severe substance use disorder\n* Diagnosis of schizophrenia, history of prior psychosis, anxiety requiring hospitalization, or Type 1 bipolar.\n* Hypernatremia\n* Hypokalemia (but can have received repletion during the prior 24 hours)\n* Hyperkalemia\n* Glomerular filtration rate of \\\u003C 30 ml\u002Fmin\n* Elevated of white blood cell count\n* Hemoglobin \\\u003C 7 g\u002Fdl\n* Platelet count \\\u003C 100,000 g\u002Fdl\n* Acute cardiac dysfunction demonstrated by either troponin elevation (chronic elevation is acceptable), or EKG changes suggestive of acute coronary syndrome.\n* Active suicidal ideation as assess by the C-SSRS.",{"count":106,"type":21},20,[108],"PHASE1","The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.",[27,111,112,113,114,115,116,117,118,119,29,120],"Chronic Stroke","Intracerebral Haemorrhage","Intracerebral Haemorrhage (ICH)","Intracerebral Hemorrhage Basal Ganglia","Ischemic Stroke","Ischemic Stroke and Hemorrhagic Stroke","Hemiparesis After Stroke","Hemiplegia Following Ischemic Stroke","Hemiplegia and Hemiparesis","Middle Cerebral Artery Stroke",[122,123,124,125,126,127,128,129,130,131],"psychedelic","stroke","chronic stroke","intracerebral hemorrhage","stroke recovery","motor recovery","poststroke recovery","poststroke motor recovery","hemiparesis recovery","psychedelic safety","2026-02-11",{"date":134,"type":40},"2026-02-13",{"date":136,"type":40},"2026-02-09",{"date":138,"type":21},"2027-03",{"name":140,"class":47},"Johns Hopkins University",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":153,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":70},"100615942","the-effect-of-virtual-reality-therapy-on-upper-extremity-functions-in-subacute-stroke-patients-receiving-rehabilitation-100615942","NCT07299162","The Effect of Virtual Reality Therapy on Upper Extremity Functions in Subacute Stroke Patients Receiving Rehabilitation","The Effect of Virtual Reality Therapy on Upper Extremity Functions in Subacute Stroke Patients Receiving Conventional Rehabilitation and Action Observation Therapy: A Randomized Controlled Single-Blind Study","Inclusion Criteria:\n\n* Patients over the age of 18\n* Patients in the subacute phase of stroke (between 6 weeks and 6 months post-stroke)\n* Patients with a first-ever stroke\n* Brunnstrom stage 3 or above for both upper extremity and hand\n* Mini-Mental State Examination (MMSE) score \\>=20\n\nNo major medical condition that would prevent participation in the treatment\n\nExclusion Criteria:\n\n* Presence of pain in the paretic shoulder severe enough to prevent exercise\n* History of bilateral stroke\n* Patients with global aphasia and\u002For cognitive impairment that significantly affects treatment compliance\n* Patients with severe visual impairment\n* Presence of unilateral spatial neglect\n* Inability to maintain sitting balance\n* Modified Ashworth Scale \\> 4 in the hemiplegic arm",{"count":149,"type":21},38,[24],"Stroke ranks second among the leading causes of death worldwide and third among the causes of disability. In stroke patients, motor impairment typically affects facial movements and the upper and lower extremities unilaterally. Upper extremity involvement, in particular, negatively impacts patients' activities of daily living, such as eating and dressing. Various rehabilitation methods are used to improve the function of the paretic upper extremity in stroke patients. Action Observation Therapy and Virtual Reality are among the rehabilitation approaches currently used to support upper extremity rehabilitation.\n\nIn our study, patients will be randomly divided into two groups: one group will receive conventional rehabilitation and Action Observation Therapy, while the other group will additionally receive Virtual Reality therapy. This study aims to investigate the contribution of Virtual Reality therapy, when added to conventional rehabilitation and Action Observation Therapy, to the recovery of the paretic upper extremity in patients with subacute stroke.",[27,29],[154,155,156,157,123,158],"Virtual reality","action observation therapy","hemiplegia","hemiparesis","upper extremity","2026-01-26",{"date":161,"type":40},"2026-01-28",{"date":163,"type":40},"2025-08-15",{"date":165,"type":21},"2026-04-20",{"name":167,"class":168},"Istanbul Physical Medicine Rehabilitation Training and Research Hospital","OTHER_GOV",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":180,"phases":4,"briefSummary":181,"conditions":182,"keywords":188,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":70},"100612468","prospective-evaluation-of-atrial-fibrillation-related-stroke-patients-in-rehabilitation-program-pearl-an-observational-cohort-study-100612468","NCT07253974","Prospective Evaluation of Atrial Fibrillation-Related Stroke Patients in Rehabilitation Program (PEARL), an Observational Cohort Study","Prospective Evaluation of Atrial Fibrillation-Related Stroke Patients in Rehabilitation Program (PEARL), an Observational Cohort Study. TARGET: Health Virtual Twins for the Personalised Management of Stroke Related to Atrial Fibrillation\".","PEARL","Inclusion Criteria:\\> 18 a, first-ever intracerebral ischemic stroke\n\n\\-\n\nExclusion Criteria:\n\n* intracranial haemorrhage, symptomatic hemorrhagic transformation, new infarcts after the initial stroke or other neurological or psychiatric conditions.","99 Years",{"count":179,"type":21},213,"OBSERVATIONAL","The goal of this observational study is to determine if rehabilitation program intensity impacts functional recovery and specific needs in adult ischemic stroke patients who require inpatient rehabilitation. The main questions it aims to answer are:\n\nDo patients with stroke of Atrial-related subtypes (AFRS) have distinct rehabilitation needs and functional outcomes compared to non-AFRS patients? Does higher-intensity inpatient rehabilitation (3-5 sessions\u002Fday) result in better functional recovery at six months (measured by the Barthel Index) than moderate-intensity programs (1 session\u002Fday)? The study is non-invasive, does not interfere with usual care. The investigators' ultimate goal is to enhance the understanding of recovery after following different rehabilitation usual programs.",[183,184,185,186,29,187],"STROKE","Rehabilitation Outcome","Brain Disease","Cardiovascular Disease Acute","Disability Physical",[189,123,190,191,192],"functional outcomes","disability","rehabilitation","high intensity rehabilitation program","2025-12-11",{"date":195,"type":40},"2025-12-15",{"date":197,"type":40},"2024-11-11",{"date":199,"type":21},"2027-12-01",{"name":201,"class":47},"Parc de Salut Mar",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":209,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":70},"100563359","immersive-vs-non-immersive-virtual-reality-in-enhancing-upper-limb-functions-among-individuals-with-subacute-stage-hemiplegia-100563359","NCT06615141","Immersive v\u002Fs Non-immersive Virtual Reality in Enhancing Upper Limb Functions Among Individuals With Subacute Stage Hemiplegia","Immersive Versus Non-immersive Virtual Reality in Enhancing Upper Limb Functions Among Individuals With Subacute Stage Hemiplegia - A Randomized Controlled Trial","Inclusion Criteria:\n\n* Individuals aged 28-55 years.\n* Diagnosed with hemiplegia due to stroke.\n* ≤ Grade 2 on Modified Ashworth scale.\n* ≤ Stage 2 on Brunnstrom stages of motor recovery.\n* Score of ≥ 35\u002F36 on Cognitive assessment scale for stroke patients (CASP)\n\nExclusion Criteria:\n\n* Contraindications for VR therapy, such as severe motion sickness or photosensitive epilepsy, impaired spatial awareness.\n* Pre-existing neurological conditions such as spinal cord injury, Multiple sclerosis and so affecting upper limb function.","28 Years","55 Years",{"count":212,"type":21},30,[24],"The goal of this randomized controlled trial is to compare the effectiveness of immersive virtual reality combined with conventional therapy to the effectiveness of non-immersive virtual reality combined with conventional therapy in enhancing upper limb function in subacute hemiplegic stroke patients.",[29],[217,218,219,220,221],"virtual reality","hemiplegic stroke","Oculus Quest 3","Motor function","Upper limb","2024-09-25",{"date":224,"type":40},"2024-09-26",{"date":226,"type":40},"2024-03-05",{"date":228,"type":21},"2025-01-05",{"name":230,"class":47},"Gulf Medical University"]